c105744.htm - Prepared by Imprima

 

 

 

 


 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549
 

________________

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

October 26, 2011

________________

 

        NOVO NORDISK A/S        
(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X]     

     Form 40-F [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ]     

      No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________

 

 

 


 

 

logo.gif

Company Announcement

26 October 2011

Novo Nordisk A/S – Share repurchase programme

On 11 August 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk has repurchased B shares for an amount up to DKK 2.1 billion in the period from 11 August 2011 to 25 October 2011. The programme is now concluded.

Since the announcement as of 17 October 2011, the following transactions have been made under the programme:

 

 

Number of

Average

Transaction value,

 

shares

purchase price

DKK

Accumulated, last
announcement

3,309,026

 

1,808,975,659

17 October 2011

80,000

524.7200

41,977,600

18 October 2011

75,000

521.2806

39,096,045

19 October 2011

75,000

524.6700

39,350,250

20 October 2011

75,000

529.0200

39,676,500

21 October 2011

75,000

535.2800

40,146,000

24 October 2011

75,000

534.0900

40,056,750

25 October 2011

70,126

537.9050

37,721,126

Accumulated under
the programme

3,834,152

 

2,086,999,930

 

With the transactions stated above, Novo Nordisk owns a total of 21,724,574 treasury shares, corresponding to 3.7% of the share capital. The total amount of shares in the company is 580,000,000 including treasury shares.

 

         

Company Announcement no 66 / 2011

Page 1 of 2

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 6626

Internet:

novonordisk.com

CVR no:

24256790

 


 

 

Novo Nordisk expects to repurchase B shares worth DKK 10.0 billion during 2011. As of 25 October 2011, Novo Nordisk has repurchased a total of 15,106,205 B shares equal to a transaction value of DKK 8,999,068,636.

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 32,000 employees in 74 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

 

Further information:

 

 

Media:

Investors:

 

Anne Margrethe Hauge

Klaus Bülow Davidsen

Tel: (+45) 4442 3450

Tel: (+45) 4442 3176

amhg@novonordisk.com

klda@novonordisk.com

 

 

Frank Daniel Mersebach

 

Tel: (+45) 4442 0604

 

fdni@novonordisk.com

 

 

Lars Borup Jacobsen

 

Tel: (+45) 3075 3479

 

lbpj@novonordisk.com

In North America:

 

Ken Inchausti

Jannick Lindegaard

Tel: (+1) 609 514 8316

Tel: (+1) 609 786 4575

kiau@novonordisk.com

jlis@novonordisk.com

 

 

         

Company Announcement no 66 / 2011

Page 2 of 2

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 6626

Internet:

novonordisk.com

CVR no:

24256790

 

 

 


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: October 26, 2011

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer